Immunopharmacology

Immunosuppressive drugs: the first 50 years and a glance forward
pp. 63-83(21)
Author: Allison A.C.

Mycophenolate mofetil and its mechanisms of action
pp. 85-118(34)
Authors: Allison A.C.; Eugui E.M.

Mechanisms of action of cyclosporine
pp. 119-125(7)
Authors: Matsuda S.; Koyasu S.

Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors
pp. 127-162(36)
Authors: Souness J.E.; Aldous D.; Sargent C.

The structure of inosine 5'-monophosphate dehydrogenase and the design of novel inhibitors
pp. 163-184(22)
Authors: Sintchak M.D.; Nimmesgern E.

Inhibition of p38 MAP kinase as a therapeutic strategy
pp. 185-201(17)
Authors: Lee J.C.; Kumar S.; Griswold D.E.; Underwood D.C.; Votta B.J.; Adams J.L.

Applications of tacrolimus for the treatment of skin disorders
pp. 203-213(11)
Authors: Assmann T.; Homey B.; Ruzicka T.

The use of mycophenolate mofetil in transplant recipients
pp. 215-245(31)
Authors: Mele T.S.; Halloran P.F.

Mechanisms of action of methotrexate
pp. 247-257(11)
Authors: Genestier L.; Paillot R.; Quemeneur L.; Izeradjene K.; Revillard J.-P.

Methotrexate use in rheumatoid arthritis. A clinician's perspective
pp. 259-271(13)
Author: Alarcon G.S.

Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases
pp. 273-289(17)
Authors: Herrmann M.L.; Schleyerbach R.; Kirschbaum B.J.

The use of leflunomide in the treatment of rheumatoid arthritis: an experimental and clinical review
pp. 291-298(8)
Author: Schattenkirchner M.